Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Agmatine is a naturally occurring chemical compound formed by the decarboxylation of the amino acid L-arginine, catalyzed by arginine decarboxylase. It is present in many organisms and acts as a neuromodulator and neurotransmitter. Agmatine exerts modulatory effects on multiple molecular targets, including neurotransmitter systems, ion channels, nitric oxide (NO) synthesis (as an inhibitor of NO synthase), polyamine metabolism, and imidazoline receptors (as an endogenous agonist). Pharmacologically, it has been studied for its potential roles in lowering blood glucose and blood pressure, diuresis, anti-inflammation, antidepressant effects, inhibition of cell proliferation, muscle growth support (especially among athletes), appetite stimulation, mood support, and alleviation of neuropathic pain. It also shows antagonistic activity at N-methyl-D-aspartate receptors[1][2][6][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on agmatine.